-
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its targets to reduce greenhouse gas (GHG) emissions have been approved by the Science Based Targets initiative (SBTi), providing external validation of the Company’s ambitious commitments to minimize its environmental footprint. As one of the world's largest manufacturers of generic medicines, Teva makes treatments more affordable and accessible - reaching nearly 200 million patients every day. With its vast global p
-
Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targets and Strengthened ESG Governance Structure Tue, 05/10/2022 - 09:00 Type of Content Press Release Layout Featured Media Body Environmental, Social and Governance (ESG) efforts integrated into business strategy with strengthened oversight, robust targets and sustainability-linked bond (SLB) Progress toward targets to improve access to medicines, including launch of four programs to-date (50%
-
Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets Wed, 11/03/2021 - 07:00 Subheader $5 billion bond is the largest of its kind from any sector and the first issued by a generic medicines company Type of Content Press Release Layout Standard Format Body TEL AVIV, Israel, November 3, 2021 /3BL Media/ - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced ambitious commitments to address two of today’s
-
SOURCE: Novartis SUMMARY:Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and managemen
-
Novartis is building a leading focused medicines company powered by advanced therapy platforms and data science.
-
Collaboration to address product development and scale up challenges posed by current pandemic SOURCE: Novartis DESCRIPTION:BASEL, Switzerland, March 26, 2020/3BL Media/ - Today, Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. The industry brings a range of assets, resources, and expertise needed to identify effective
-
The Government of Ghana announced the availability of hydroxyurea for the treatment of people with SCD marking the official launch of a first of its kind public-private partnership to improve the diagnosis and accelerate treatment for people with SCD